Yasuyoshi Miyata Selected Research

royal jelly

12/2021	Effect of oral intake of royal jelly on endothelium function in hemodialysis patients: study protocol for multicenter, double-blind, randomized control trial.
12/2020	Erratum: Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial.
11/2020	Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2.
10/2020	Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators.
10/2020	Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial.
12/2018	Oral Intake of Royal Jelly Has Protective Effects Against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial.
10/2018	Anti-Cancer and Protective Effects of Royal Jelly for Therapy-Induced Toxicities in Malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yasuyoshi Miyata Research Topics

Disease

76	Neoplasms (Cancer) 05/2022 - 09/2002
29	Renal Cell Carcinoma (Grawitz Tumor) 06/2022 - 03/2003
27	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 02/2003
23	Urinary Bladder Neoplasms (Bladder Cancer) 08/2021 - 02/2006
18	Neoplasm Metastasis (Metastasis) 01/2022 - 02/2006
8	Overactive Urinary Bladder (Overactive Bladder) 07/2022 - 07/2016
6	Lower Urinary Tract Symptoms 03/2022 - 07/2016
6	Non-Muscle Invasive Bladder Neoplasms 01/2022 - 01/2015
6	Carcinogenesis 10/2021 - 01/2017
4	Disease Progression 01/2022 - 08/2014
4	Urologic Neoplasms (Urological Cancer) 01/2018 - 02/2013
4	Carcinoma (Carcinomatosis) 08/2012 - 06/2005
3	Spinal Cord Diseases 07/2021 - 01/2018
3	Tropical Spastic Paraparesis (Tropical Spastic Paraplegia) 07/2021 - 01/2018
3	Fatigue 10/2020 - 10/2015
3	Nocturia 04/2019 - 01/2017
3	Pain (Aches) 10/2015 - 11/2005
3	Transitional Cell Carcinoma 06/2006 - 03/2004
2	Hypertension (High Blood Pressure) 03/2022 - 12/2015
2	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2022 - 01/2021
2	Erectile Dysfunction 01/2022 - 07/2004
2	Atherosclerosis 12/2021 - 08/2005
2	Renal Insufficiency (Renal Failure) 12/2021 - 01/2013
2	Hypoxia (Hypoxemia) 08/2021 - 03/2007
2	Anorexia 10/2020 - 12/2018
2	Chronic Kidney Failure (Chronic Renal Failure) 08/2019 - 07/2019
2	Autoimmune Diseases (Autoimmune Disease) 10/2018 - 01/2017
2	Sarcoma (Soft Tissue Sarcoma) 01/2018 - 06/2013
2	Peritonitis 01/2014 - 09/2006
2	Fibrosis (Cirrhosis) 01/2013 - 12/2005

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 05/2022 - 09/2002
10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2020 - 03/2003
10	Matrix Metalloproteinases (MMPs)IBA 05/2019 - 05/2003
7	royal jellyIBA 12/2021 - 10/2018
7	Cisplatin (Platino)FDA LinkGeneric 12/2020 - 06/2011
7	Gemcitabine FDA Link 07/2020 - 06/2011
6	Dinoprostone (PGE2)FDA Link 10/2021 - 01/2005
6	AntigensIBA 10/2018 - 01/2016
6	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2017 - 05/2003
5	mirabegronIBA 07/2022 - 07/2016
5	Biomarkers (Surrogate Marker)IBA 08/2021 - 11/2007
5	PolyphenolsIBA 01/2021 - 06/2010
5	Paclitaxel (Taxol)FDA LinkGeneric 11/2019 - 12/2011
5	TeaIBA 01/2019 - 06/2010
4	ProstaglandinsIBA 10/2021 - 01/2013
4	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 07/2020 - 05/2003
4	Vascular Endothelial Growth FactorsIBA 01/2017 - 02/2006
4	Formaldehyde (Formol)FDA Link 12/2014 - 01/2005
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2011 - 03/2003
4	Proto-Oncogene Proteins c-metIBA 04/2009 - 03/2003
3	Pharmaceutical PreparationsIBA 07/2022 - 10/2018
3	Sunitinib (Sutent)FDA Link 01/2022 - 06/2018
3	Macrophage Colony-Stimulating FactorIBA 12/2021 - 08/2005
3	stage-specific embryonic antigen-4IBA 07/2021 - 10/2019
3	ThrombospondinsIBA 05/2021 - 05/2003
3	SaltsIBA 01/2021 - 01/2017
3	Tyrosine Kinase InhibitorsIBA 11/2020 - 12/2018
3	Biological ProductsIBA 11/2020 - 06/2013
3	Heme Oxygenase-1IBA 07/2020 - 12/2014
3	4N1K peptideIBA 05/2019 - 05/2003
3	AntibodiesIBA 01/2017 - 08/2006
3	Matrix Metalloproteinase 2 (Gelatinase A)IBA 04/2009 - 05/2003
3	Phosphotransferases (Kinase)IBA 01/2009 - 03/2003
2	CalciumIBA 03/2022 - 08/2005
2	Immune Checkpoint InhibitorsIBA 01/2022 - 04/2020
2	8-Hydroxy-2'-DeoxyguanosineIBA 12/2021 - 08/2021
2	Malondialdehyde (Propanedial)IBA 12/2021 - 08/2021
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2021 - 10/2018
2	Hormones (Hormone)IBA 09/2021 - 01/2016
2	Antigen-Antibody Complex (Immune Complex)IBA 08/2021 - 01/2017
2	Ceruloplasmin (Ferroxidase)IBA 08/2021 - 07/2021
2	Androgen Receptors (Androgen Receptor)IBA 07/2021 - 01/2019
2	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2020 - 10/2017
2	AntioxidantsIBA 05/2019 - 10/2018
2	Thrombospondin 1IBA 05/2019 - 06/2013
2	Small Interfering RNA (siRNA)IBA 01/2018 - 01/2009
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018 - 06/2013
2	CreatinineIBA 01/2018 - 01/2014
2	AndrogensIBA 04/2017 - 01/2017
2	Vascular Endothelial Growth Factor CIBA 01/2017 - 02/2006
2	Guanosine Triphosphate (GTP)IBA 01/2017 - 06/2010
2	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 03/2015 - 08/2005
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 12/2014 - 01/2009
2	Vascular Endothelial Growth Factor DIBA 12/2014 - 02/2006
2	NitrosaminesIBA 01/2013 - 06/2010
2	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2011 - 02/2009
2	Matrix Metalloproteinase 7 (Matrilysin)IBA 11/2009 - 12/2006
2	Tyrosine (L-Tyrosine)FDA Link 04/2009 - 08/2006
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 02/2008 - 07/2006

Therapy/Procedure

35	Therapeutics 01/2022 - 02/2003
9	Prostatectomy (Retropubic Prostatectomy) 01/2022 - 06/2004
5	Castration 09/2021 - 01/2016
5	Drug Therapy (Chemotherapy) 04/2020 - 04/2006
4	Nephrectomy 06/2022 - 01/2009
4	Molecular Targeted Therapy 12/2020 - 08/2014
4	Aftercare (After-Treatment) 01/2018 - 09/2012
3	Renal Dialysis (Hemodialysis) 12/2021 - 07/2004
3	Renal Replacement Therapy (Therapies, Renal Replacement) 12/2021 - 07/2019
2	Radiotherapy 08/2014 - 04/2006
2	Combination Drug Therapy (Combination Chemotherapy) 12/2011 - 06/2011